Tyra Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-69.13	-55.33	-26.29	-9.34	-4.07
Depreciation & Amortization	0.35	0.3	0.14	0.05	0.01
Share-Based Compensation	13.53	10.59	2.89	0.44	0
Other Operating Activities	5.12	-5.84	-0.48	1.09	1.44
Operating Cash Flow	-50.14	-50.29	-23.75	-7.76	-2.62
Capital Expenditures	-0.77	-0.56	-0.65	-0.31	-0.02
Change in Investments	-143.84	0	0	0	0
Investing Cash Flow	-144.61	-0.56	-0.65	-0.31	-0.02
Share Issuance / Repurchase	1.54	0.63	181.73	0.14	0
Debt Issued / Paid	0	0	-0.01	-0.02	0.16
Other Financing Activities	-	-	129.62	23.31	-
Financing Cash Flow	1.54	0.63	311.35	23.43	0.16
Net Cash Flow	-193.21	-50.21	286.96	15.36	-2.48
Free Cash Flow	-50.91	-50.84	-24.39	-8.08	-2.64
Free Cash Flow Per Share	-1.19	-1.21	-1.77	-5.24	-2.58

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).